Rinat Neuroscience Corporation

Labrys Biologics, Inc.

Teva Pharmaceuticals International Gmbh

Pfizer Corporation

Talem Therapeutics LLC

Carterra, Inc.

Yasmina Noubia Abdiche

Jaume Pons

Arnon Rosenthal

Kristian Todd Poulsen

Joerg Zeller

Sierra Jones Collier

Javier Fernando Chaparro Riggers

Hong Liang

Julie Jia Li Hawkins

Bruce Charles Gomes

Yuli Wang

Arvind Rajpal

Sawsan Youssef

Karin Ute Jooss

Weihsien Ho

Helen Kim Cho

Ilse Roodink

Jennifer L Bath

Pavel Strop

Wei-Hsien Ho

Xiayang Qiu

Joshua Wayne Eckman

Adam Miles

Sierra Lee Jones Collier

Sierra Leigh Jones Collier

Julie Jia Hawkins

The present application relates to neutralizing antibodies or antigen-binding fragments thereof against betacoronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), to nucleic acid(s) encoding such neutralizing antibodies or antigen-binding fragments thereof, and to mixture and compositions comprising such antibodies, antigen-binding fragments or nucleic acids. Such neutralizing antibodies or antigen-binding fragments thereof are able to block betacoronavirus entry into cells and/or to induce complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and/or antibody-dependent cellular phagocytosis (ADCP) against betacoronavirus-infected cells. Methods and uses of the antibodies, antigen-binding fragments thereof, nucleic acid(s) or compositions, including therapeutic, diagnostic, and preventative methods and uses for betacoronavirus infections and related diseases such as COVID-19, are also described.

Anti-spike glycoprotein antibodies and the therapeutic use thereof

The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.

Anti-PD-1 antibodies and methods of use thereof

A system and method for sensing and analyzing antibody blocking interactions is described. A biosensor can be used to identify interactions between antibodies to generate interaction profiles for the antibodies. A processor can be used to assign the antibodies to one or more bins, with the antibodies sharing a common interaction profile assigned to a common bin, and each antibody only being assigned to one bin. The antibodies can be represented by displaying nodes grouped together for antibodies in a common bin. Connections between the nodes can be displayed, representing interactions between the antibodies.

Systems and methods of sensing and analyzing antibody blocking interactions

The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.

Methods for treating headache using antagonist antibodies directed against calcitonin gene-related peptide

Antagonist antibodies directed against calcitonin gene-related peptide

Methods of using anti-CGRP antagonist antibodies

Antagonist antibodies directed against calcitonin gene-related peptide and methods using same

Growing community of inventors

Mountain View, CA, United States of America

Yasmina Noubia Abdiche